- WW International Inc, known as WeightWatchers, said on Monday it is acquiring subscription telehealth platform Sequence, moving the weight-loss program operator into the obesity drug prescription business.
Launched in 2021, Sequence now serves about 24,000 members across the U.S., as of February 2023, and clocks about $25 million in annual revenue on a run-rate basis.
It's all the rage now. Lots of $$ to be made.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
WeightWatchers to buy Sequence telehealth, enter obesity drug prescription businessWW International Inc, known as WeightWatchers, said on Monday it is acquiring subscription telehealth platform Sequence, moving the weight-loss program operator into the obesity drug prescription business. WeighWatchers said it expects its $132 million acquisition in cash and stock will complement its nutrition and behavior-change program for weight loss at a time when obesity drugs are seen as one of the biggest markets for drugmakers.
مصدر: YahooNews - 🏆 380. / 59 اقرأ أكثر »
WSJ News Exclusive | WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors. Isn't moving into the Ozempic market an implicit admission that their product doesn't work. 'You can totally lose weight and keep it off with our points system... but on second thought, here's some drugs.' 황금으로 만든 골든 이글이 필요해
مصدر: WSJhealth - 🏆 413. / 53 اقرأ أكثر »
WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors.
مصدر: WSJhealth - 🏆 413. / 53 اقرأ أكثر »